What is Texas Cap Bancsh's earnings per share (EPS)?

Texas Cap Bancsh (TCBIO) reported diluted earnings per share of $6.79 for fiscal year 2025. This represents a 430.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Texas Cap Bancsh (TCBIO) Financials

TCBIO

Trailing 12 months to June 30, 2026

Revenue $1.8B +0.4% YoY

Net Income $364.6M +171.9% YoY

EPS (Diluted) $7.69 +206.4% YoY

Free Cash Flow $471.2M +22.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 23, 2026 Currency USD FYE December

Newest figures come from the 10-K for Q2 FY2026, filed Jul 23, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TCBIO SEC filings page.

Texas Cap Bancsh (TCBIO) reported $1.8B in revenue over the twelve months to Jun 30, 2026, up 0.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TCBIO FY2025 2026-08-29

A balance-sheet-heavy business where declining leverage and volatile interest expense shape earnings more than modest revenue growth.

Between FY2024 and FY2025, net margin rose from 4.5% to 18.6%, despite revenue barely changing. Interest expense also declined from $828M to $743M, indicating financing costs—not just operating growth—helped drive the earnings rebound.

Debt-to-equity declined from 0.3x in FY2022 to 0.2x in FY2025, showing a less debt-intensive capital structure. Liabilities still stood at $27.9B in FY2025, so the lower ratio does not describe a lightly financed balance sheet.

Cash conversion changed character: FY2024 operating cash flow was $480M while net income was only $78M, a wide gap consistent with substantial non-cash or working-capital effects. In FY2025, operating cash flow and free cash flow were much closer at $360M and $348M, indicating limited cash consumption by reinvestment.

Financial Health Signals

Financial health score not available

Texas Cap Bancsh does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

6/7

Texas Cap Bancsh passes 6 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.09x

For every $1 of reported earnings, Texas Cap Bancsh generates $1.09 in operating cash flow ($360.2M OCF vs $330.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$439.9M

YoY+0.1%

QoQ+5.0%

5Y CAGR+15.2%

10Y CAGR+9.8%

Texas Cap Bancsh generated $439.9M in revenue in Q2 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is up 5.0%.

Net Income

$84.9M

YoY+9.9%

QoQ+15.1%

5Y CAGR+2.9%

10Y CAGR+8.1%

Texas Cap Bancsh reported $84.9M in net income in Q2 2026. This represents an increase of 9.9% from the same quarter a year earlier. Against the prior quarter it is up 15.1%.

EPS (Diluted)

$1.83

YoY+15.8%

QoQ+17.3%

5Y CAGR+6.9%

10Y CAGR+8.9%

Texas Cap Bancsh earned $1.83 per diluted share (EPS) in Q2 2026. This represents an increase of 15.8% from the same quarter a year earlier. Against the prior quarter it is up 17.3%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$93.5M

YoY+62.7%

QoQ+8.5%

5Y CAGR-17.2%

Texas Cap Bancsh generated $93.5M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 62.7% from the same quarter a year earlier. Against the prior quarter it is up 8.5%.

Cash & Debt

$3.7B

YoY+37.5%

QoQ+25.1%

5Y CAGR-11.9%

10Y CAGR+3.1%

Texas Cap Bancsh held $3.7B in cash against $500.9M in long-term debt as of Q2 2026.

Dividends Per Share

$0.20

Texas Cap Bancsh paid $0.20 per share in dividends in Q2 2026.

Shares Outstanding

43M

YoY-5.0%

QoQ-0.5%

5Y CAGR-3.0%

10Y CAGR-0.6%

Texas Cap Bancsh had 43M shares outstanding in Q2 2026. This represents a decrease of 5.0% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Margins & Returns

Net Margin

19.3%

YoY+1.7pp

QoQ+1.7pp

5Y CAGR-14.6pp

10Y CAGR-3.2pp

Texas Cap Bancsh's net profit margin was 19.3% in Q2 2026, showing the share of revenue converted to profit. This is up 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.

Return on Equity

2.3%

YoY+0.1pp

QoQ+0.3pp

5Y CAGR0.0pp

10Y CAGR0.0pp

Texas Cap Bancsh's ROE was 2.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Capital Allocation

Share Buybacks

$23.6M

YoY+12.2%

QoQ-68.6%

Texas Cap Bancsh spent $23.6M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 12.2% from the same quarter a year earlier. Against the prior quarter it is down 68.6%.

Capital Expenditures

$10.0M

YoY+80.3%

QoQ+636.6%

5Y CAGR+76.0%

Texas Cap Bancsh invested $10.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 80.3% from the same quarter a year earlier. Against the prior quarter it is up 636.6%.

R&D Spending

Not reported for Q2 2026.

TCBIO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TCBIO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$1.8B	$1.8B+2.4%	$1.7B+6.1%	$1.6B+42.4%	$1.1B+30.5%	$876.5M-15.7%	$1.0B-23.3%	$1.4B+16.4%	$1.2B+32.4%	$879.3M+25.0%	$703.4M+16.7%	$603.0M+17.2%	$514.5M+15.7%	$444.6M+11.6%	$398.5M+267320.8%	$149K
SG&A Expenses	$491.4M	$480.5M+3.0%	$466.6M+1.5%	$459.7M+5.7%	$434.9M+24.2%	$350.2M+2.8%	$340.5M+3.7%	$328.5M+9.2%	$300.9M+12.9%	$266.5M+16.4%	$229.0M+18.9%	$192.6M+13.9%	$169.1M+7.2%	$157.8M+29.9%	$121.5M+20.8%	$100.5M
Interest Expense	$709.6M	$743.1M-10.3%	$828.3M+15.7%	$715.8M+166.6%	$268.5M+149.2%	$107.7M-42.7%	$188.1M-51.2%	$385.6M+54.6%	$249.3M+111.4%	$118.0M+85.5%	$63.6M+37.0%	$46.4M+23.5%	$37.6M+49.7%	$25.1M+16.4%	$21.6M+15.6%	$18.7M
Income Tax	$111.9M	$102.5M+246.7%	$29.6M-48.6%	$57.5M-42.1%	$99.3M+18.0%	$84.1M+227.8%	$25.7M-69.6%	$84.3M+5.4%	$80.0M-37.8%	$128.6M+49.5%	$86.1M+8.1%	$79.6M+4.8%	$76.0M+13.9%	$66.8M-1.6%	$67.9M+60.4%	$42.3M
Net Income	$364.6M	$330.2M+326.1%	$77.5M-59.0%	$189.1M-43.1%	$332.5M+30.9%	$253.9M+283.1%	$66.3M-78.8%	$312.0M+6.3%	$293.4M+49.6%	$196.1M+26.4%	$155.1M+7.1%	$144.9M+6.2%	$136.4M+12.6%	$121.1M+0.3%	$120.7M+58.8%	$76.0M
EPS (Basic)	N/A	$6.86+431.8%	$1.29-64.0%	$3.58-42.7%	$6.25+34.4%	$4.65+315.2%	$1.12-81.4%	$6.01+5.8%	$5.68+50.3%	$3.78+20.4%	$3.14+6.4%	$2.95+0.7%	$2.93+5.4%	$2.78-10.0%	$3.09+52.2%	$2.03
EPS (Diluted)	$7.69	$6.79+430.5%	$1.28-63.8%	$3.54-42.7%	$6.18+34.3%	$4.60+310.7%	$1.12-81.3%	$5.99+6.2%	$5.64+51.2%	$3.73+19.9%	$3.11+6.9%	$2.91+1.0%	$2.88+5.9%	$2.72-9.3%	$3.00+51.5%	$1.98
Diluted Shares (Avg)	N/A	46M-1.8%	47M-3.3%	49M-4.8%	51M-0.2%	51M+1.1%	51M+0.3%	50M+0.3%	50M0.0%	50M+7.5%	47M+0.7%	46M+5.5%	44M+5.3%	42M+4.0%	40M+4.8%	38M

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-K	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$439.9M+0.1%	$419.1M-1.9%	$444.3M+1.5%	$460.6M+1.8%	$439.6M+4.1%	$427.3M+2.4%	$437.6M+4.9%	$452.5M+6.3%
SG&A Expenses	$123.3M+2.7%	$139.3M+5.9%	$108.9M+11.2%	$119.9M-1.1%	$120.2M+1.1%	$131.6M+2.3%	$97.9M-9.4%	$121.1M+10.1%
Interest Expense	$179.6M-3.6%	$164.4M-14.1%	$176.9M-14.9%	$188.8M-11.1%	$186.2M-9.4%	$191.3M-5.5%	$208.0M+2.8%	$212.4M+9.7%
Income Tax	$27.1M+8.8%	$20.6M+53.8%	$31.6M+40.6%	$32.6M+274.4%	$24.9M+46.8%	$13.4M+52.5%	$22.5M+323.3%	-$18.7M-196.4%
Net Income	$84.9M+9.9%	$73.8M+56.8%	$100.7M+41.7%	$105.2M+271.6%	$77.3M+85.6%	$47.0M+80.0%	$71.0M+252.5%	-$61.3M-199.4%
EPS (Basic)	$1.85+16.4%	$1.58+69.9%	$2.14+49.7%	$2.21+255.6%	$1.59+98.8%	$0.93+102.2%	$1.43+320.6%	-$1.42-219.3%
EPS (Diluted)	$1.83+15.8%	$1.56+69.6%	$2.12+49.3%	$2.18+254.6%	$1.58+97.5%	$0.92+100.0%	$1.42+317.6%	-$1.41-219.5%
Diluted Shares (Avg)	44M-4.7%	45M-4.3%	N/A	46M-0.8%	46M-1.4%	47M-2.3%	N/A	47M-4.0%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Operating Income, EBITDA.

TCBIO Balance Sheet

TCBIO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$31.5B+2.6%	$30.7B+8.4%	$28.4B-0.2%	$28.4B-18.2%	$34.7B-7.9%	$37.7B+15.9%	$32.5B+15.2%	$28.3B+12.7%	$25.1B+15.6%	$21.7B+14.8%	$18.9B+18.8%	$15.9B+35.7%	$11.7B+11.2%	$10.5B+29.5%	$8.1B
Cash & Equivalents	$2.1B-34.2%	$3.2B-1.7%	$3.2B-35.3%	$5.0B-36.9%	$7.9B-13.7%	$9.2B+108.0%	$4.4B+43.7%	$3.1B+6.0%	$2.9B+2.3%	$2.8B+58.5%	$1.8B+34.6%	$1.3B+764.5%	$153.9M-25.4%	$206.3M+86.6%	$110.6M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$1.5M0.0%	$1.5M0.0%	$1.5M0.0%	$1.5M-90.1%	$15.1M0.0%	$15.1M0.0%	$15.1M0.0%	$15.1M0.0%	$15.1M0.0%	$15.1M0.0%	$15.1M+0.7%	$15.0M0.0%	$15.0M+6.8%	$14.0M0.0%	$14.0M
Total Liabilities	$27.9B+2.0%	$27.4B+8.8%	$25.2B-0.8%	$25.4B-19.6%	$31.5B-9.6%	$34.9B+17.2%	$29.7B+15.4%	$25.8B+12.6%	$22.9B+16.2%	$19.7B+13.9%	$17.3B+19.8%	$14.4B+35.7%	$10.6B+9.5%	$9.7B+29.0%	$7.5B
Long-Term Debt	$620.6M-6.0%	$660.3M-23.1%	$859.1M-7.8%	$931.4M+0.3%	$928.7M+134.6%	$395.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.6B+7.8%	$3.4B+5.3%	$3.2B+4.7%	$3.1B-4.8%	$3.2B+11.8%	$2.9B+2.5%	$2.8B+12.9%	$2.5B+13.3%	$2.2B+9.6%	$2.0B+23.1%	$1.6B+9.4%	$1.5B+35.4%	$1.1B+31.1%	$836.2M+35.7%	$616.3M
Retained Earnings	$2.8B+12.5%	$2.5B+2.5%	$2.4B+7.6%	$2.3B+16.2%	$1.9B+13.7%	$1.7B+3.0%	$1.7B+22.2%	$1.4B+26.3%	$1.1B+20.9%	$891.5M+17.6%	$757.8M+21.7%	$622.7M+25.5%	$496.1M+29.7%	$382.5M+46.1%	$261.8M

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-K	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$33.9B+6.2%	$33.5B+6.7%	$31.5B+2.6%	$32.5B+2.9%	$31.9B+7.0%	$31.4B+7.5%	$30.7B+8.4%	$31.6B+6.8%
Cash & Equivalents	$3.7B+37.5%	$3.0B-22.2%	$2.1B-34.2%	$3.1B-26.9%	$2.7B-7.7%	$3.8B+14.7%	$3.2B-1.7%	$4.2B0.0%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	$1.5M0.0%	N/A	N/A	N/A	$1.5M0.0%	N/A
Total Liabilities	$30.3B+6.4%	$29.9B+6.9%	$27.9B+2.0%	$28.9B+2.2%	$28.4B+6.6%	$27.9B+7.4%	$27.4B+8.8%	$28.3B+6.5%
Long-Term Debt	$500.9M-19.2%	$878.3M+33.0%	$620.6M-6.0%	$620.4M-6.0%	$620.3M-6.0%	$660.5M-23.2%	$660.3M-23.1%	$660.2M-23.1%
Total Equity	$3.6B+3.9%	$3.6B+5.1%	$3.6B+7.8%	$3.6B+8.4%	$3.5B+10.5%	$3.4B+8.2%	$3.4B+5.3%	$3.4B+9.0%
Retained Earnings	$3.0B+13.0%	$2.9B+13.4%	$2.8B+12.5%	$2.7B+11.7%	$2.6B+4.7%	$2.5B+3.3%	$2.5B+2.5%	$2.4B+0.4%

Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Current Liabilities, Non-Current Liabilities.

TCBIO Cash Flow Statement

TCBIO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$487.8M	$360.2M-25.0%	$480.1M+28.5%	$373.7M+152.6%	$148.0M-77.5%	$657.3M-75.1%	$2.6B+1199.1%	-$240.2M+64.7%	-$679.7M-614.3%	$132.2M+118.2%	-$726.3M-1153.5%	$68.9M-56.3%	$157.7M-17.6%	$191.4M+114.4%	$89.3M+17.7%	$75.9M
Depreciation & Amortization	N/A	$52.2M-3.8%	$54.2M+34.0%	$40.5M-10.6%	$45.3M-51.5%	$93.4M+24.7%	$74.9M+101.0%	$37.3M+16.4%	$32.0M+14.9%	$27.9M+27.8%	$21.8M+32.2%	$16.5M+11.5%	$14.8M+28.9%	$11.5M+21.6%	$9.4M+3.7%	$9.1M
Stock-Based Compensation	N/A	$36.8M+48.9%	$24.7M+2.0%	$24.2M+12.9%	$21.4M-31.6%	$31.3M+79.6%	$17.4M-0.9%	$17.6M+3.9%	$16.9M-23.1%	$22.0M+62.2%	$13.6M+10.4%	$12.3M-15.6%	$14.6M-30.4%	$21.0M+74.3%	$12.0M+63.7%	$7.3M
Capital Expenditures	$16.0M	$12.6M-80.6%	$64.8M+295.8%	$16.4M+45.4%	$11.3M+173.1%	$4.1M+47.6%	$2.8M-83.2%	$16.7M+117.6%	$7.7M-37.6%	$12.3M+463.6%	$2.2M-56.8%	$5.0M-68.0%	$15.7M+290.5%	$4.0M+13.9%	$3.5M+7.7%	$3.3M
Free Cash Flow	$471.2M	$347.6M-16.3%	$415.2M+16.2%	$357.4M+161.4%	$136.7M-79.1%	$653.2M-75.2%	$2.6B+1126.7%	-$256.8M+62.6%	-$687.4M-673.3%	$119.9M+116.5%	-$728.5M-1239.9%	$63.9M-55.0%	$142.0M-24.2%	$187.3M+118.5%	$85.7M+18.1%	$72.6M
Investing Cash Flow	-$1.0B	-$1.9B+25.2%	-$2.5B-41.2%	-$1.8B-153.1%	$3.3B+168.4%	$1.2B+142.0%	-$2.9B-29.0%	-$2.3B-14.2%	-$2.0B+38.0%	-$3.2B-278.2%	-$850.2M+65.4%	-$2.5B+17.5%	-$3.0B-133.9%	-$1.3B+43.6%	-$2.3B	N/A
Financing Cash Flow	$1.6B	$404.3M-79.2%	$1.9B+601.4%	-$387.7M+93.9%	-$6.4B-102.9%	-$3.1B-162.1%	$5.1B+31.4%	$3.9B+35.6%	$2.8B-9.6%	$3.1B+20.0%	$2.6B-8.0%	$2.9B-28.7%	$4.0B+287.8%	$1.0B-54.5%	$2.3B	N/A
Share Buybacks	$232.4M	$185.8M+128.0%	$81.5M-22.4%	$105.0M-8.9%	$115.3M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-K	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$103.5M+64.3%	$87.5M+23685.1%	$130.5M+615.9%	$166.3M-50.0%	$63.0M+89.3%	$368K-99.6%	$18.2M-90.3%	$332.8M+248.8%
Depreciation & Amortization	$15.6M+7.6%	$12.8M+39.0%	$15.9M+3.7%	$12.6M-10.4%	$14.5M+3.8%	$9.2M-15.5%	$15.3M+59.4%	$14.1M+26.3%
Stock-Based Compensation	$9.8M+28.1%	$17.5M+37.2%	N/A	$8.2M+27.6%	$7.6M+22.6%	$12.8M+49.4%	N/A	$6.5M+45.3%
Capital Expenditures	$10.0M+80.3%	$1.4M-43.8%	-$341K-95.4%	$5.0M-67.4%	$5.5M-75.0%	$2.4M-87.9%	$7.4M+98.4%	$15.2M+95.5%
Free Cash Flow	$93.5M+62.7%	$86.2M+4307.6%	$130.2M+1102.6%	$161.3M-49.2%	$57.5M+419.1%	-$2.0M-102.7%	$10.8M-94.1%	$317.6M+262.4%
Investing Cash Flow	$304.8M+118.8%	-$1.1B-4733.9%	$36.2M+115.1%	-$245.7M+46.2%	-$1.6B-66.9%	-$23.6M+97.1%	-$240.2M-175.4%	-$456.4M-170.9%
Financing Cash Flow	$333.4M-25.2%	$1.9B+200.2%	-$1.1B-45.0%	$454.1M-67.6%	$445.7M-16.7%	$636.9M-19.1%	-$780.8M+46.4%	$1.4B+131.4%
Share Buybacks	$23.6M+12.2%	$75.1M+141.2%	$126.6M+486884.6%	$7.1M	$21.0M-58.0%	$31.2M-1.2%	-$26K-99.9%	$0

Not reported in any period shown, so not listed: Dividends Paid.

TCBIO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TCBIO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Net Margin	18.6%+14.2pp	4.5%-7.1pp	11.6%-17.5pp	29.1%+0.1pp	29.0%+22.6pp	6.4%-16.7pp	23.0%-2.2pp	25.2%+2.9pp	22.3%+0.3pp	22.1%-2.0pp	24.0%-2.5pp	26.5%-0.7pp	27.2%-3.1pp	30.3%	50990.6%
Return on Equity	9.1%+6.8pp	2.3%-3.6pp	5.9%-5.0pp	10.9%+3.0pp	7.9%+5.6pp	2.3%-8.8pp	11.1%-0.7pp	11.8%+2.9pp	8.9%+1.2pp	7.8%-1.2pp	8.9%-0.3pp	9.2%-1.9pp	11.0%-3.4pp	14.4%+2.1pp	12.3%
Return on Assets	1.1%+0.8pp	0.3%-0.4pp	0.7%-0.5pp	1.2%+0.4pp	0.7%+0.5pp	0.2%-0.8pp	1.0%-0.1pp	1.0%+0.3pp	0.8%+0.1pp	0.7%-0.1pp	0.8%-0.1pp	0.9%-0.2pp	1.0%-0.1pp	1.1%+0.2pp	0.9%
Debt-to-Equity	0.170.0x	0.20-0.1x	0.270.0x	0.300.0x	0.29+0.2x	0.14-10.5x	10.62+0.2x	10.39-0.1x	10.45+0.6x	9.85-0.8x	10.64+0.9x	9.720.0x	9.69-1.9x	11.61-0.6x	12.20
Asset Turnover	0.060.0x	0.060.0x	0.060.0x	0.040.0x	0.030.0x	0.030.0x	0.040.0x	0.040.0x	0.040.0x	0.030.0x	0.030.0x	0.030.0x	0.040.0x	0.040.0x	0.00
FCF Margin	19.6%-4.4pp	24.0%+2.1pp	21.9%+10.0pp	11.9%-62.6pp	74.5%	253.7%	-19.0%+40.1pp	-59.0%-72.7pp	13.6%	-103.6%	10.6%-17.0pp	27.6%-14.5pp	42.1%+20.6pp	21.5%	48702.7%

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-K	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Net Margin	19.3%+1.7pp	17.6%+6.6pp	22.7%+6.4pp	22.8%+36.4pp	17.6%+7.7pp	11.0%+4.8pp	16.2%+11.4pp	-13.6%-28.0pp
Return on Equity	2.3%+0.1pp	2.1%+0.7pp	2.8%+0.7pp	2.9%+4.7pp	2.2%+0.9pp	1.4%+0.5pp	2.1%+1.5pp	-1.8%-3.8pp
Return on Assets	0.3%0.0pp	0.2%+0.1pp	0.3%+0.1pp	0.3%+0.5pp	0.2%+0.1pp	0.1%+0.1pp	0.2%+0.2pp	-0.2%-0.4pp
Debt-to-Equity	0.140.0x	0.24+0.1x	0.170.0x	0.170.0x	0.180.0x	0.19-0.1x	0.20-0.1x	0.20-0.1x
Asset Turnover	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.010.0x
FCF Margin	21.3%+8.2pp	20.6%+21.0pp	29.3%+26.8pp	35.0%-35.1pp	13.1%+10.5pp	-0.5%-18.6pp	2.5%-41.6pp	70.2%+49.6pp

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Current Ratio.

Where Texas Cap Bancsh Ranks

Frequently Asked Questions

What is Texas Cap Bancsh's annual revenue?

Texas Cap Bancsh (TCBIO) reported $1.8B in total revenue for fiscal year 2025. This represents a 2.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Texas Cap Bancsh's revenue growing?

Texas Cap Bancsh (TCBIO) revenue grew by 2.4% year-over-year, from $1.7B to $1.8B in fiscal year 2025.

Is Texas Cap Bancsh profitable?

Yes, Texas Cap Bancsh (TCBIO) reported a net income of $330.2M in fiscal year 2025, with a net profit margin of 18.6%.

How much debt does Texas Cap Bancsh have?

As of fiscal year 2025, Texas Cap Bancsh (TCBIO) had $2.1B in cash and equivalents against $620.6M in long-term debt.

What is Texas Cap Bancsh's net profit margin?

Texas Cap Bancsh (TCBIO) had a net profit margin of 18.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Texas Cap Bancsh's return on equity (ROE)?

Texas Cap Bancsh (TCBIO) has a return on equity of 9.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Texas Cap Bancsh's free cash flow?

Texas Cap Bancsh (TCBIO) generated $347.6M in free cash flow during fiscal year 2025. This represents a -16.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Texas Cap Bancsh's operating cash flow?

Texas Cap Bancsh (TCBIO) generated $360.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Texas Cap Bancsh's total assets?

Texas Cap Bancsh (TCBIO) had $31.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Texas Cap Bancsh's capital expenditures?

Texas Cap Bancsh (TCBIO) invested $12.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Texas Cap Bancsh buy back shares?

Yes, Texas Cap Bancsh (TCBIO) spent $185.8M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Texas Cap Bancsh have outstanding?

Texas Cap Bancsh (TCBIO) had 44M shares outstanding as of fiscal year 2025.

What is Texas Cap Bancsh's debt-to-equity ratio?

Texas Cap Bancsh (TCBIO) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Texas Cap Bancsh's return on assets (ROA)?

Texas Cap Bancsh (TCBIO) had a return on assets of 1.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Texas Cap Bancsh's Piotroski F-Score?

Texas Cap Bancsh (TCBIO) has a Piotroski F-Score of 6 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Texas Cap Bancsh's earnings high quality?

Texas Cap Bancsh (TCBIO) has an earnings quality ratio of 1.09x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.